<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alyssa R Letourneau, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. Beta-lactam antibiotics include:</p><p class="bulletIndent1"><span class="glyph">●</span>Penicillins</p><p class="bulletIndent1"><span class="glyph">●</span>Cephalosporins</p><p class="bulletIndent1"><span class="glyph">●</span>Cephamycins</p><p class="bulletIndent1"><span class="glyph">●</span>Carbapenems</p><p class="bulletIndent1"><span class="glyph">●</span>Monobactams</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-lactamase inhibitors</p><p></p><p>Since this category of antibiotics is so broad, it is important to subdivide these drugs into functional drug groups to facilitate understanding and prescribing practices. It is not necessary for clinicians to know every drug within each of these groups. The grouping of these agents can be based on spectrum of activity, choice of agents for an antibiotic formulary, therapeutic use, or routine susceptibility testing. Within each functional group, differences between antibiotics in pharmacokinetics, safety, duration of the clinical experience with their use, and cost allow reasonable choices to be made in selecting an individual drug as representative of that group.</p><p>The mechanisms of action and resistance and major adverse reactions to these antibiotics will be reviewed here. The penicillins, cephalosporins, and novel beta-lactam drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/473.html" rel="external">"Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins"</a> and  <a class="medical medical_review" href="/d/html/480.html" rel="external">"Cephalosporins"</a> and  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics inhibit the growth of sensitive bacteria by inactivating enzymes located in the bacterial cell membrane, which are involved in the third stage of cell wall synthesis. It is during this stage that linear strands of peptidoglycan are cross-linked into a fishnet-like polymer that surrounds the bacterial cell and confers osmotic stability in the hypertonic milieu of the infected patient. Beta-lactams inhibit not just a single enzyme involved in cell wall synthesis, but a family of related enzymes (four to eight in different bacteria), each involved in different aspects of cell wall synthesis. These enzymes can be detected by their covalent binding of radioactively-labeled penicillin (or other beta-lactams) and hence have been called penicillin-binding proteins (PBPs).</p><p>Different PBPs appear to serve different functions for the bacterial cell. As an example, PBP2 in <em>Escherichia coli</em> is important in maintaining the rod-like shape of the bacillus, while PBP3 is involved in septation during cell division [<a href="#rid1">1</a>]. Different beta-lactam antibiotics may preferentially bind to and inhibit certain PBPs more than others. Thus, different agents may produce characteristic effects on bacterial morphology and have different efficacies in inhibiting bacterial growth or killing the organism.</p><p>Beta-lactam antibiotics are generally bactericidal against organisms that they inhibit. The mechanism of bacterial cell killing is an indirect consequence of the inhibition of bacterial cell wall synthesis. Enzymes that mediate autolysis of peptidoglycan are normally present in the bacterial cell wall but are strictly regulated to allow breakdown of the peptidoglycan only at growing points. Beta-lactam inhibition of cell wall synthesis leads to activation of the autolytic system through a two-component system, VncR/S, which initiates a cell death program [<a href="#rid2">2</a>].</p><p>Certain bacteria are deficient in these autolytic enzymes or have mutations in the regulatory genes; these strains show the phenomenon of "tolerance" to beta-lactam antibiotics, that is, their growth is inhibited by the antibiotic, but the bacteria are not killed.</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISMS OF BACTERIAL RESISTANCE</span><span class="headingEndMark"> — </span>Three general mechanisms of bacterial resistance to antibiotics, including the beta-lactams, have been well characterized: decreased penetration to or increased efflux from the target site; alteration of the target site; and inactivation of the antibiotic by a bacterial enzyme [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Decreased penetration to the target site and efflux</span><span class="headingEndMark"> — </span>The outer membrane of gram-negative bacilli provides an efficient barrier to the penetration of beta-lactam antibiotics to their target penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane. Beta-lactams usually must pass through the hydrophilic porin protein channels in the outer membrane of gram-negative bacilli to reach the periplasmic space and cytoplasmic membrane. The permeability barrier of the outer membrane is a major factor in the relative intrinsic resistance of <em>Pseudomonas aeruginosa</em> to many beta-lactam antibiotics. Mutations that result in decreased amounts of porin channels, those that increase the amounts of native active efflux pumps, or both can contribute to acquired resistance to beta-lactams.</p><p class="headingAnchor" id="H5"><span class="h2">Alteration of the target site</span><span class="headingEndMark"> — </span>The target sites for the beta-lactams are the PBPs in the cytoplasmic membrane. Alterations in PBPs may influence their binding affinity for beta-lactam antibiotics and therefore the sensitivity of the altered bacterial cell to inhibition by these antibiotics. Such a mechanism is responsible for penicillin resistance in pneumococci [<a href="#rid5">5</a>], methicillin (<a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>) resistance in staphylococci [<a href="#rid6">6</a>], and for bacteria with increasing intrinsic resistance to beta-lactams, such as gonococci, enterococci, and <em>Haemophilus influenzae</em>.</p><p class="headingAnchor" id="H6"><span class="h2">Inactivation by a bacterial enzyme</span><span class="headingEndMark"> — </span>Production of beta-lactamases is a major mechanism of resistance to the beta-lactam antibiotics in clinical isolates. Such bacterial enzymes may cleave predominantly penicillins (penicillinases), cephalosporins (cephalosporinases), or both (beta-lactamases). Their production may be encoded within the bacterial chromosome (and hence be characteristic of an entire species) or the genes may be acquired on a plasmid or transposon (and hence be characteristic of an individual strain rather than the species). Bacteria may synthesize the beta-lactamase constitutively (as for many plasmid-mediated enzymes) or synthesis may be inducible in the presence of antibiotic (as for many chromosomal enzymes). Inducible beta-lactamases may not be reliably detected by initial susceptibility testing, particularly with the newer rapid methods.</p><p class="headingAnchor" id="H7"><span class="h3">Chromosomal beta-lactamases</span><span class="headingEndMark"> — </span>Although virtually all gram-negative bacilli possess a chromosomal beta-lactamase gene, certain species express insignificant amounts of this enzyme, and their susceptibility to beta-lactams is largely determined by plasmid-mediated beta-lactamases and antibiotic permeability. These include <em>E. coli</em>, <em>Proteus mirabilis</em>, <em>Salmonella</em>, <em>Shigella</em>, and <em>H. influenzae</em>. <em>Klebsiella pneumoniae</em> produces a chromosomal beta-lactamase that is primarily a penicillinase; thus, these strains are frequently more susceptible to the cephalosporins. The last group of species within the Enterobacterales, including <em>Enterobacter</em>, indole-positive <em>Proteus</em>, <em>Morganella</em>, <em>Serratia</em>, and <em>Citrobacter</em>, can produce an inducible chromosomal beta-lactamase, AmpC, that may be difficult to detect on initial susceptibility testing but that can mediate resistance to all currently available beta-lactams with the exception of the carbapenems and, in some cases, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> [<a href="#rid7">7-9</a>]. In addition to inducible production of this chromosomal enzyme, these species may give rise to regulatory mutants that are "derepressed" and produce high levels of this broad-spectrum chromosomal enzyme constitutively. Per expert guidelines, <em>Enterobacter cloacae </em>complex, <em>Klebsiella aerogenes</em> (formerly, <em>Enterobacter aerogenes</em>), and <em>Citrobacter freundii</em> are<em> </em>the Enterobacterales with moderate to high risk for clinically significant AmpC production in the United States [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H8"><span class="h3">Plasmid-mediated beta-lactamases</span><span class="headingEndMark"> — </span>The most common plasmid-mediated beta-lactamases of gram-negative bacteria (such as TEM-1, TEM-2, and SHV-1) mediate resistance to the penicillins and first- and some of the second-generation cephalosporins, but not <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a>, cephamycins, third- and fourth-generation cephalosporins, carbapenems, or <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>.</p><p>Extended-spectrum plasmid-mediated beta-lactamases (ESBLs; derived from the common TEM and SHV enzymes) are now common and are capable of cleaving later-generation cephalosporins and <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> [<a href="#rid11">11</a>]. Originally described in strains of <em>Klebsiella</em> from Europe, these beta-lactamases are found in a variety of gram-negative bacilli in many areas of the United States and spread between patients in intensive care units has been documented. In addition, a study from Chicago documented that nursing home patients may be an important reservoir for strains of Enterobacterales producing extended-spectrum plasmid-mediated beta-lactamases [<a href="#rid12">12</a>]. In one nursing home, for example, 18 of 39 patients were colonized with such resistant strains, and of the 55 patients in an acute care hospital colonized with resistant <em>E. coli</em> or <em>K. pneumoniae</em>, 35 had been admitted from nursing homes, and 31 of them were colonized on admission. Although the strains of resistant <em>E. coli</em> and <em>K. pneumoniae</em> differed, most harbored a common plasmid-encoded extended-spectrum beta-lactamase, suggesting intraspecies and interspecies transfer of plasmids between strains, rather than transfer of a single strain between patients. All of these strains were resistant to <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, and <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, and 96 and 41 percent were also resistant to <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, respectively.</p><p>ESBLs, of which there are many varieties, mediate high-level resistance to the third- and fourth-generation cephalosporins and <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>, but not to the cephamycins (<a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> and <a class="drug drug_general" data-topicid="9222" href="/d/drug information/9222.html" rel="external">cefotetan</a>) or the carbapenems. Use of the cephamycins against strains containing these enzymes is, however, limited by the development of permeability mutants in the porin protein, OmpF. The beta-lactamase inhibitors, clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, and relebactam have generally retained the ability to inhibit ESBLs. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases"</a>.)</p><p>Another plasmid-mediated beta-lactamase, MIR-1, has been described in <em>Klebsiella</em>; it is homologous to the AmpC chromosomal beta-lactamase of <em>E. cloacae</em> [<a href="#rid13">13</a>]. This plasmid-mediated beta-lactamase is capable of cleaving all of the currently available beta-lactams (with the exception of the carbapenems) and its activity is <strong>not</strong> inhibited by clavulanate, sulbactam, or tazobactam. This plasmid-mediated beta-lactamase confers a broad resistance pattern similar to that of stably derepressed mutants of <em>Enterobacter</em>. </p><p>Over the past two decades, carbapenem-hydrolyzing enzymes have been described in <em>K. pneumoniae</em> and other members of the Enterobacterales. These are encoded on transmissible plasmids, which facilitate their spread. Resistance to the carbapenems in these strains is not always detected by currently available automated susceptibility methods. (See  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Classifications and geographic distribution'</a>.)</p><p>The New Delhi metallo-beta-lactamase 1 (NDM-1) is another plasmid-mediated enzyme that mediates broad resistance to all currently available beta-lactams (including the carbapenems) and is linked to other resistance genes on the plasmid that can confer resistance to all available antibiotics, with the exceptions of <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>, <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a>, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>, and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid14">14-16</a>]. This enzyme was originally found in a number of Enterobacterales in India and Pakistan as well as in individuals returning to the UK, United States, and other countries who have travelled there, particularly for medical care; they have now been found more broadly. Organisms containing metallo-beta-lactamases have been referred to in the lay media as "superbugs" because of their extensive resistance. (See  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Classifications and geographic distribution'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Several adverse reactions have been described for beta-lactam antibiotics.</p><p class="headingAnchor" id="H10"><span class="h2">IgE-mediated allergic reactions</span><span class="headingEndMark"> — </span>Type I, IgE-mediated reactions present with various combinations of pruritus, flushing, urticaria, angioedema, wheezing, laryngeal edema, hypotension, and/or anaphylaxis. Symptoms usually appear within four hours of drug administration and may begin within minutes. When the allergy first develops, the initial symptoms may appear during the later days of treatment and then escalate rapidly. (See  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Serum sickness</span><span class="headingEndMark"> — </span>Serum sickness is a late allergic reaction characterized by fever, rash (usually urticarial), adenopathy, arthritis, and occasionally glomerulonephritis. It is associated with circulating immune complexes and has been reported with all of the beta-lactam antibiotics. Each of the beta-lactam antibiotics is also capable of causing drug fever. (See  <a class="medical medical_review" href="/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a> and  <a class="medical medical_review" href="/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a> and  <a class="medical medical_review" href="/d/html/2738.html" rel="external">"Drug fever"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Dermatologic reactions</span><span class="headingEndMark"> — </span>A variety of rashes occur with the beta-lactam antibiotics, of which morbilliform rash is the most common. Erythema multiforme is an acute eruption characterized by distinctive target skin lesions and diagnostic histology; when the mucosal surfaces are involved as well, the reaction is termed Stevens-Johnson syndrome. Exfoliative dermatitis is a severe skin disorder with generalized erythema and scaling. Toxic epidermal necrolysis is an acute severe reaction with widespread erythema and detachment of the epidermis; there may be a positive Nikolsky sign. Hypersensitivity angiitis is a small vessel vasculitis involving mainly the venules of the skin and characterized by palpable purpura. The beta-lactam antibiotics may also cause photosensitivity reactions. (See  <a class="medical medical_review" href="/d/html/5559.html" rel="external">"Erythema multiforme: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2089.html" rel="external">"Drug eruptions"</a> and  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Neurologic reactions</span><span class="headingEndMark"> — </span>Among the antibiotics, the penicillins are the most common to cause encephalopathy. Penicillin neurotoxicity is characterized by a change in the level of consciousness (somnolence, stupor, or coma) with generalized hyperreflexia, myoclonus, and seizures. This syndrome occurs with high-dose penicillin therapy (&gt;20 million units per day), particularly if excretion is delayed by underlying renal disease or if preexisting neurologic disease is present. Penicillin neurotoxicity can potentially confuse the management of patients with bacterial meningitis.</p><p>High doses of the beta-lactam antibiotics (particularly penicillins, fourth-generation cephalosporins, and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>) may cause seizures [<a href="#rid17">17</a>]. Central nervous system (CNS) toxicity of imipenem correlates with high doses, renal dysfunction, or underlying CNS disease [<a href="#rid17">17,18</a>]. <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> has also been associated with seizures, particularly in the setting of renal impairment. Between 1996 and 2012, 59 cases of nonconvulsive status epilepticus during cefepime use in patients with renal dysfunction were reported to the United States Food and Drug Administration (FDA) [<a href="#rid19">19</a>]. Most cases occurred in patients whose dose was not appropriately adjusted for renal function and resolved following hemodialysis or discontinuation of cefepime. </p><p><a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> neurotoxicity can also manifest as changes in level of consciousness, disorientation or agitation, and myoclonus as described in two systematic reviews; older patients with renal dysfunction are at increased risk [<a href="#rid20">20,21</a>]. An observational study of 503 patients receiving cefepime reported that 4 percent (22 patients) experienced cefepime-related neurotoxicity, with a greater risk in those with higher drug levels and those with renal dysfunction [<a href="#rid22">22</a>]. In a randomized trial comparing cefepime to <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> in over 2500 hospitalized patients, 21 percent of patients on cefepime experienced delirium or coma compared with 17 percent on piperacillin-tazobactam; patients on cefepime experienced fewer days alive and were free of delirium (11.9 days) than patients on piperacillin-tazobactam (12.2 days; OR 0.79; 95% CI, 0.65 to 0.95) [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">Pulmonary reactions</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics occasionally cause the pulmonary infiltrate with eosinophilia (PIE) syndrome, which has an abrupt onset with fever, chills, dyspnea, pulmonary infiltrates, and peripheral eosinophilia (see  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a>). Beta-lactam antibiotics may also cause drug-induced lupus, with manifestations including serositis (pleural effusions or pericarditis), fever, and pneumonia. (See  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Gastrointestinal reactions</span><span class="headingEndMark"> — </span>Diarrhea is a frequent nonspecific complication of antibiotic therapy, especially with certain oral antibiotics such as <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> or <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> [<a href="#rid24">24</a>]. All antibiotics can predispose to <em>Clostridioides </em>(formerly <em>Clostridium</em>) <em>difficile</em> colitis, including penicillins and cephalosporins. (See  <a class="medical medical_review" href="/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Antibiotic use'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Hepatobiliary reactions</span><span class="headingEndMark"> — </span>The semisynthetic penicillins, such as <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a> and <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, may cause hypersensitivity hepatitis accompanied by fever, rash, and eosinophilia [<a href="#rid25">25</a>]. This syndrome is more commonly seen at higher doses. <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> may cause biliary sludge and pseudocholelithiasis, particularly in children [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Renal reactions</span><span class="headingEndMark"> — </span>Several types of reactions can occur in the kidneys.</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerulonephritis may be seen in association with hypersensitivity angiitis or serum sickness following administration of beta-lactam antibiotics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cephalosporin antibiotics may potentiate the renal toxicity of aminoglycosides.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In observational studies, concomitant use of <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> has been associated with acute kidney injury [<a href="#rid27">27-29</a>]. However, a randomized trial comparing <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> to piperacillin-tazobactam in over 1900 hospitalized patients who were also on vancomycin found that the incidence of major kidney events at day 14 was comparable between groups (10 percent in the cefepime group compared with 9 percent in the piperacillin-tazobactam group; absolute difference, 1.4 percent; 95% CI -1.0 to 3.8 percent) [<a href="#rid23">23</a>]. The median duration of antibiotic treatment was three days, and there was substantial crossover of study drugs (approximately 18 percent in both groups). Based on these data, we believe the risk of nephrotoxicity from coadministration of vancomycin and piperacillin-tazobactam is less than that suggested by observational data. For patients who warrant prolonged coadministration of vancomycin with an antipseudomonal agent, we weigh the potential risk of nephrotoxicity against possible drawbacks of other beta-lactams, such as risk of neurotoxicity with cefepime or overly broad coverage with carbapenems. (See  <a class="medical medical_review" href="/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults", section on 'Acute kidney injury'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The beta-lactam antibiotics, particularly methicillin and <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, may cause allergic interstitial nephritis [<a href="#rid30">30</a>], characterized by acute, often severe, renal failure, with an active urinary sediment with hematuria, proteinuria, and pyuria, but generally no red cell casts (see  <a class="medical medical_review" href="/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis"</a>). Signs of hypersensitivity are generally present, including fever, peripheral eosinophilia, and rash; eosinophiluria is characteristic but not always found.</p><p></p><p>There are several case reports of cross-sensitivity between beta-lactam antibiotics eliciting acute allergic interstitial nephritis, so the occurrence of this syndrome with one beta-lactam antibiotic generally cautions against the use of other agents in this class.</p><p>The antipseudomonal penicillins, particularly ticarcillin (which is a disodium salt), may cause sodium overload and hypokalemic alkalosis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Hematologic reactions</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics may be associated with immune-mediated destruction of polymorphonuclear leukocytes, which is characterized by an abrupt onset of neutropenia with fever, rash, and eosinophilia. Similarly, beta-lactam antibiotics may cause immune-mediated hemolytic anemia, characterized by a positive non-gamma Coombs' test or by subacute extravascular hemolysis with a positive gamma Coombs' test. This latter reaction generally requires prolonged, high-dose therapy and signs of hypersensitivity are usually absent.</p><p>Acute immune thrombocytopenia has been associated with beta-lactam antibiotic administration. The platelet count generally normalizes within two weeks after the drug is stopped. Platelet dysfunction may be caused by high doses of ticarcillin; the newer antipseudomonal penicillin, <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>, has less of an effect on platelet function [<a href="#rid31">31,32</a>].</p><p>Broad spectrum antibiotic therapy suppresses gut flora and may contribute to vitamin K deficiency. Hypoprothrombinemia has been a particular problem with antibiotics containing the N-methylthiotetrazole side chain [<a href="#rid33">33</a>]. This same side chain is associated with intolerance to ethanol.</p><p class="headingAnchor" id="H2221080281"><span class="h1">USE OF BETA-LACTAM ANTIBIOTICS IN THE PENICILLIN OR CEPHALOSPORIN-ALLERGIC PATIENT</span><span class="headingEndMark"> — </span>Penicillins and cephalosporins may be safe to use in the allergic patient. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical terminology.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/138962.html" rel="external">"Patient education: Carbapenem-resistant enterobacterales (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/367.html" rel="external">"Patient education: Allergy to penicillin and related antibiotics (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29594957"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Beta-lactam antibiotics inhibit the growth of sensitive bacteria by inactivating enzymes located in the bacterial cell membrane, known as penicillin-binding proteins (PBPs), which are involved in cell wall synthesis. These antibiotics are generally bactericidal against susceptible organisms. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of resistance</strong> – The major mechanism of resistance to the beta-lactam antibiotics in clinical isolates is production of enzymes that cleave penicillins (penicillinases), cephalosporins (cephalosporinases), or both (beta-lactamases). Decreased penetration to the cytoplasmic membrane target site and alterations in the PBPs are other mechanisms of resistance. (See <a class="local">'Mechanisms of bacterial resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromosomal beta-lactamases</strong> – <em>Enterobacter cloacae </em>complex, <em>Klebsiella aerogenes</em>, and <em>Citrobacter freundii</em> are at moderate to high risk for producing an inducible chromosomal beta-lactamase, AmpC, that may be difficult to detect on initial susceptibility testing but can mediate resistance to all currently available beta-lactams other than carbapenems and, in some cases, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>. (See <a class="local">'Chromosomal beta-lactamases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmid-mediated beta-lactamases</strong> – The most common plasmid-mediated beta-lactamases in gram-negative bacteria mediate resistance to penicillins and first- and some second-generation cephalosporins. Extended spectrum plasmid-mediated beta-lactamases can additionally cleave later-generation cephalosporins and <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>. These plasmids can transfer to other species and genera. (See <a class="local">'Plasmid-mediated beta-lactamases'</a> above and  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Use of beta-lactams is associated with various adverse effects, including IgE-mediated allergic reactions, rash, diarrhea, renal toxicity, and other hypersensitivity and immune-mediated reactions. The penicillins are the most common antibiotics to cause encephalopathy and high doses of beta-lactams can cause seizures. (See <a class="local">'Adverse effects'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spratt BG, Cromie KD. Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis 1988; 10:699.</a></li><li><a class="nounderline abstract_t">Novak R, Charpentier E, Braun JS, Tuomanen E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 2000; 5:49.</a></li><li><a class="nounderline abstract_t">Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335:1445.</a></li><li><a class="nounderline abstract_t">Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.</a></li><li><a class="nounderline abstract_t">Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.</a></li><li><a class="nounderline abstract_t">Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995; 21:1107.</a></li><li><a class="nounderline abstract_t">Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781.</a></li><li><a class="nounderline abstract_t">Siedner MJ, Galar A, Guzmán-Suarez BB, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 2014; 58:1554.</a></li><li><a class="nounderline abstract_t">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Katsanis GP, Spargo J, Ferraro MJ, et al. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol 1994; 32:691.</a></li><li><a class="nounderline abstract_t">Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517.</a></li><li><a class="nounderline abstract_t">Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990; 34:2200.</a></li><li><a class="nounderline abstract_t">Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597.</a></li><li><a class="nounderline abstract_t">Camargo CH, Yamada AY, Souza AR, et al. Genomic Diversity of NDM-Producing Klebsiella Species from Brazil, 2013-2022. Antibiotics (Basel) 2022; 11.</a></li><li><a class="nounderline abstract_t">Zou X, Jin S, Chen L, et al. Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study. Infect Drug Resist 2023; 16:2271.</a></li><li><a class="nounderline abstract_t">Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015; 85:1332.</a></li><li><a class="nounderline abstract_t">Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14:435.</a></li><li class="breakAll">FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, June 26, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm309661.htm (Accessed on June 27, 2012).</li><li><a class="nounderline abstract_t">Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care 2017; 21:276.</a></li><li><a class="nounderline abstract_t">Appa AA, Jain R, Rakita RM, et al. Characterizing Cefepime Neurotoxicity: A Systematic Review. Open Forum Infect Dis 2017; 4:ofx170.</a></li><li><a class="nounderline abstract_t">Venugopalan V, Casaus D, Kainz L, et al. Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity. Pharmacotherapy 2023; 43:6.</a></li><li><a class="nounderline abstract_t">Qian ET, Casey JD, Wright A, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA 2023; 330:1557.</a></li><li><a class="nounderline abstract_t">Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ 2015; 187:E21.</a></li><li><a class="nounderline abstract_t">Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med 1978; 89:497.</a></li><li><a class="nounderline abstract_t">Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.</a></li><li><a class="nounderline abstract_t">Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis 2016.</a></li><li><a class="nounderline abstract_t">Navalkele B, Pogue JM, Karino S, et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. Clin Infect Dis 2017; 64:116.</a></li><li><a class="nounderline abstract_t">Rutter WC, Cox JN, Martin CA, et al. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Ditlove J, Weidmann P, Bernstein M, Massry SG. Methicillin nephritis. Medicine (Baltimore) 1977; 56:483.</a></li><li><a class="nounderline abstract_t">Tan JS, File TM Jr. Antipseudomonal penicillins. Med Clin North Am 1995; 79:679.</a></li><li><a class="nounderline abstract_t">Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.</a></li><li><a class="nounderline abstract_t">Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105:924.</a></li></ol></div><div id="topicVersionRevision">Topic 479 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Penicillin-binding proteins of gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10678168" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8875923" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antimicrobial-drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236486" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994784" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antibiotic resistance in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452155" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589129" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759352" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The use of cefepime for treating AmpCβ-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647022" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37463564" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8195380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022107" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1963529" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705517" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36290053" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genomic Diversity of NDM-Producing Klebsiella Species from Brazil, 2013-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37090037" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26400582" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Seizures as adverse events of antibiotic drugs: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10829264" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cephalosporins, carbapenems, and monobactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10829264" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cephalosporins, carbapenems, and monobactams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29137682" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cefepime-induced neurotoxicity: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29071284" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characterizing Cefepime Neurotoxicity: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36401796" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37837651" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25404399" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/697229" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227290" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940946" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986669" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27895019" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/335187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Methicillin nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791416" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antipseudomonal penicillins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10829263" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3535606" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Potential for bleeding with the new beta-lactam antibiotics.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
